PMID- 25941130
OWN - NLM
STAT- MEDLINE
DCOM- 20151016
LR  - 20150505
IS  - 0026-4946 (Print)
IS  - 0026-4946 (Linking)
VI  - 67
IP  - 3
DP  - 2015 Jun
TI  - Efficacy and safety of a medical device in reducing nasal obstruction in allergic 
      children.
PG  - 239-43
AB  - AIM: Despite the availability of a number of pharmacological options, relief of 
      allergic rhinitis (AR) symptoms, especially nasal obstruction, is often limited 
      and local and systemic adverse reactions are not infrequent. The main aim of the 
      present pilot study was to provide subjective and objective evidence of the 
      clinical efficacy in reducing symptoms and safety of a medical device-Grip stop 
      DMG (lactoferrin, carboximetil beta-glucan, D-panthenol, dipotassiumglycyrrhizinate) 
      in children affected by allergic rhinitis. METHODS: A prospective study with a 
      pre- and post-design has been performed consecutively enrolling 50 pediatric both 
      genders patients affected by persistent AR. Patients received 2 puffs into each 
      nostril twice a day over the course of 4 weeks. The severity of AR symptoms was 
      assessed subjectively as measured by a 0 to 5 Visual Analog Scale, and 
      objectively through active anterior rhinomanometry (AAR) and by means of the 
      evaluation of mucociliary transport time (MCTt). Differences in symptoms scores 
      measured before and after the treatment were compared using Paired-Sample 
      Wilcoxon Signed Rank Test. Proportion of participants with adverse effects 
      attributed to the treatment was computed. The relationship between the subjective 
      score and the AAR and MCT measurements was also assessed. RESULTS: All considered 
      symptoms, including nasal congestion, significantly improved after treatment 
      (P<0.001), while only 1 patient suffered from moderate adverse effects. 
      CONCLUSION: Results confirm efficacy and safety of this device used in the 
      pediatric population. As previously reported in the scientific literature, also 
      in our study, patient's perception of nasal symptoms corresponded with objective 
      testing.
FAU - Passali, D
AU  - Passali D
AD  - Department of Otolaryngology, University of Siena, Siena, Italy - 
      d.passali@virgilio.it.
FAU - Passali, F M
AU  - Passali FM
FAU - Loglisci, M
AU  - Loglisci M
FAU - Cambi, J
AU  - Cambi J
FAU - Bellussi, L M
AU  - Bellussi LM
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Pediatr
JT  - Minerva pediatrica
JID - 0400740
RN  - 0 (beta-Glucans)
RN  - 19F5HK2737 (Pantothenic Acid)
RN  - 1O6C93RI7Z (dexpanthenol)
RN  - 61163-25-5 (carboxymethyl-beta-1,3-glucan)
RN  - 6FO62043WK (Glycyrrhizic Acid)
RN  - EC 3.4.21.- (Lactoferrin)
SB  - IM
MH  - Administration, Intranasal
MH  - Adolescent
MH  - Child
MH  - Equipment Design
MH  - Female
MH  - Glycyrrhizic Acid/administration & dosage/adverse effects
MH  - Humans
MH  - Lactoferrin/administration & dosage/adverse effects
MH  - Male
MH  - Nasal Obstruction/*drug therapy/etiology
MH  - Pantothenic Acid/administration & dosage/adverse effects/analogs & derivatives
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Rhinitis, Allergic/complications/*drug therapy
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - beta-Glucans/administration & dosage/adverse effects
EDAT- 2015/05/06 06:00
MHDA- 2015/10/17 06:00
CRDT- 2015/05/06 06:00
PHST- 2015/05/06 06:00 [entrez]
PHST- 2015/05/06 06:00 [pubmed]
PHST- 2015/10/17 06:00 [medline]
AID - R15Y2015N03A0239 [pii]
PST - ppublish
SO  - Minerva Pediatr. 2015 Jun;67(3):239-43.